RLAY Relay Therapeutics Inc

USD 8.30 0.14 1.715686
Icon

Relay Therapeutics Inc (RLAY) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 8.30

+0.14 (+1.72)%

USD 1.04B

0.68M

USD 22.00(+165.06%)

USD 28.50 (+243.37%)

Icon

RLAY

Relay Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 8.30
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 1.04B

USD 28.50 (+243.37%)

USD 8.30

Relay Therapeutics Inc (RLAY) Stock Forecast

Show ratings and price targets of :
USD 22.00
(+165.06%)

Based on the Relay Therapeutics Inc stock forecast from 2 analysts, the average analyst target price for Relay Therapeutics Inc is USD 22.00 over the next 12 months. Relay Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Relay Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Relay Therapeutics Inc’s stock price was USD 8.30. Relay Therapeutics Inc’s stock price has changed by +3.62% over the past week, -17.66% over the past month and -44.67% over the last year.

No recent analyst target price found for Relay Therapeutics Inc
No recent average analyst rating found for Relay Therapeutics Inc

Company Overview Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lea...Read More

https://www.relaytx.com

399 Binney Street, Cambridge, MA, United States, 02139

323

December

USD

USA

Adjusted Closing Price for Relay Therapeutics Inc (RLAY)

Loading...

Unadjusted Closing Price for Relay Therapeutics Inc (RLAY)

Loading...

Share Trading Volume for Relay Therapeutics Inc Shares

Loading...

Compare Performance of Relay Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for RLAY

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Relay Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.69 (+0.17%) USD107.38B 29.93 21.06

ETFs Containing RLAY

Symbol Name RLAY's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Relay Therapeutics Inc (RLAY) Stock

Based on ratings from 2 analysts Relay Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.

Unfortunately we do not have enough data on RLAY's stock to indicate if its a good dividend stock.

Based on targets from 2 analysts, the average taret price for RLAY is USD 22.00 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 17.

Unfortunately we do not have enough data on RLAY's stock to indicate if its overvalued.

The last closing price of RLAY's stock was USD 8.30.

The most recent market capitalization for RLAY is USD 1.04B.

Based on targets from 2 analysts, the average taret price for RLAY is projected at USD 22.00 over the next 12 months. This means that RLAY's stock price may go up by +165.06% over the next 12 months.

We can't find any ETFs which contains Relay Therapeutics Inc's stock.

As per our most recent records Relay Therapeutics Inc has 323 Employees.

Relay Therapeutics Inc's registered address is 399 Binney Street, Cambridge, MA, United States, 02139. You can get more information about it from Relay Therapeutics Inc's website at https://www.relaytx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...